|
市場調査レポート
商品コード
1741546
吸入可能医薬品の世界市場：薬剤クラス別、製品タイプ別、用途別、流通チャネル別、地域別Global Inhalable Drugs Market, By Drug Class, By Product Type, By Application, By Distribution Channel, By Region |
||||||
カスタマイズ可能
|
|||||||
| 吸入可能医薬品の世界市場：薬剤クラス別、製品タイプ別、用途別、流通チャネル別、地域別 |
|
出版日: 2025年03月27日
発行: Coherent Market Insights
ページ情報: 英文 206 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
世界の吸入可能医薬品市場は、2025年には400億6,000万米ドルと推定され、2032年までには651億7,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は7.2%で成長する見込みです。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024年 | 2025年の市場規模 | 400億6,000万米ドル |
| 実績データ | 2020年～2024年 | 予測期間 | 2025年～2032年 |
| 予測期間：2025年～2032年 CAGR： | 7.20% | 2032年の金額予測 | 651億7,000万米ドル |
吸入可能医薬品は、肺を経由して呼吸器官から局所的に投与され、迅速な治療効果を得ることができる医療物質です。喘息、慢性閉塞性肺疾患、嚢胞性線維症などの肺疾患の治療に特に有効です。肺は、消化管からの経口投与と比較して、薬物吸収のための巨大な表面積を提供します。吸入可能医薬品は肝初回通過代謝をバイパスするため、肺組織に直接薬剤を素早くデリバリーし、全身レベルを下げることができます。主な利点としては、経口薬と比較して、数分以内の迅速な作用発現、低用量投与、副作用の軽減などが挙げられます。人気のある吸入可能医薬品には、アルブテロールのような喘息や慢性閉塞性肺疾患用の気管支拡張剤、コルチコステロイド、分散性抗生物質、インスリンなどがあります。世界の肺疾患の増加に伴い、吸入可能な医薬品市場は今後も安定した成長が見込まれています。
市場力学：.
世界の吸入可能医薬品市場は、喘息やCOPDなどの呼吸器疾患の世界の有病率の増加によって牽引されています。例えば、2023年3月16日、世界保健機関（WHO）によると、慢性閉塞性肺疾患（COPD）は世界第3位の死因であり、2021年には3億人以上が喘息に罹患し、COPDでは毎年300万人以上が死亡しています。汚染レベルの増加とライフスタイルの変化が、肺疾患の症例数の増加に寄与しています。同市場はまた、呼吸器に直接影響を及ぼす疾患の治療において、吸入可能医薬品の優れた治療効果からも利益を得ています。定量吸入器（MDI）やドライパウダー吸入器（DPI）などのドラッグデリバリーデバイスの技術的進歩は、新規治療の機会を拡大しています。しかし、吸入可能医薬品の開発と生産に関連する高いコストが、より広い市場の成長を制限しています。さらに、肺ドラッグデリバリーシステムの臨床試験や製品承認に関する厳しい規制も制約となっています。とはいえ、先進的な製剤や併用療法に関する研究開発が進行中であるため、予測期間中に新たな道が開ける可能性があります。
本調査の主な特徴
- 本レポートは、世界の吸入可能医薬品市場を詳細に分析し、2024年を基準年とした2025年から2032年の予測期間における市場規模および複合年間成長率（CAGR）を提供しています。
- また、さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案のマトリックスについて説明しています。
- また、市場促進要因、抑制要因、機会、新製品の上市や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する主要考察も提供しています。
- 企業ハイライト、製品ポートフォリオ、主要なハイライト、財務実績、戦略などのパラメータに基づいて、世界の吸入可能医薬品市場の主要企業をプロファイルしています。
- このレポートからの洞察は、マーケティング担当者や企業の経営陣が将来の製品の発売、タイプのアップグレード、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことを可能にします。
- 吸入可能医薬品の世界市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
- 利害関係者は、世界の吸入可能医薬品市場を分析する際に使用される様々な戦略マトリックスを通じて意思決定を容易にすることができます。
目次
第1章 調査目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
- Coherent Opportunity Map（COM）
第3章 市場力学、規制、動向分析
- 市場力学
- 主なハイライト
- 規制シナリオ
- 最近の動向
- PEST分析
- PORTERの分析
- 合併、買収、提携
第4章 世界の吸入可能医薬品市場-コロナウイルス（COVID-19）パンデミックの影響
- COVID-19疫学
- 供給側と需要側の分析
- 経済への影響
第5章 世界の吸入可能医薬品市場、薬剤クラス別、2020年～2032年
- 吸入コルチコステロイド
- ロイコトリエン修飾薬
- 長時間作用型β拮抗薬（LABA）
- 長時間作用型ムスカリン拮抗薬（LAMA）
- その他
第6章 世界の吸入可能医薬品市場、製品タイプ別、2020年～2032年
- エアロゾル
- 乾燥粉末製剤
- スプレー
- その他
第7章 世界の吸入可能医薬品市場、用途別、2020年～2032年
- 呼吸器疾患
- 喘息
- 慢性閉塞性肺疾患（COPD）
- 嚢胞性線維症
- アレルギー性鼻炎
- その他
- 非呼吸器疾患
第8章 世界の吸入可能医薬品市場、流通チャネル別、2020年～2032年
- 病院薬局
- 小売薬局
- オンライン薬局
第9章 世界の吸入可能医薬品市場、地域別、2020年～2032年
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- 英国
- スペイン
- フランス
- イタリア
- ロシア
- その他欧州
- アジア太平洋
- 中国
- インド
- 日本
- オーストラリア
- 韓国
- ASEAN
- その他アジア太平洋
- ラテンアメリカ
- ブラジル
- アルゼンチン
- メキシコ
- その他ラテンアメリカ
- 中東
- GCC諸国
- イスラエル
- その他中東
- アフリカ
- 北アフリカ
- 中央アフリカ
- 南アフリカ
第10章 競合情勢
- 企業プロファイル
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck &Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
第11章 セクション
- 参照
- 調査手法
- 出版社について
Global Inhalable Drugs Market is estimated to be valued at USD 40.06 Bn in 2025 and is expected to reach USD 65.17 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 40.06 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.20% | 2032 Value Projection: | USD 65.17 Bn |
Inhalable drugs are medical substances that can be administered locally through the respiratory tract via the lung for rapid therapeutic effects. They are particularly effective for treating lung conditions such as asthma, chronic obstructive pulmonary disease and cystic fibrosis. The lung provides huge surface area for drug absorption as compared to oral administration through the gastrointestinal tract. Inhalable drugs bypass hepatic first-pass metabolism for faster delivery of medications directly to the lung tissues and lower systemic levels. Some key advantages include rapid onset of action within minutes, lower dosing, and reduced side effects as compared to oral medications. Popular inhalable drugs include bronchodilators for asthma and chronic obstructive pulmonary disease like albuterol, corticosteroids, dispersible antibiotics, and insulin. With rising lung diseases globally, the inhalable drugs market is expected to grow steadily in the future.
Market Dynamics:
Global inhalable drugs market is driven by the growing prevalence of respiratory diseases such as asthma and COPD worldwide. For instance, on March 16, 2023, according to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of death worldwide, and over 300 Mn people suffered from asthma in 2021, while over 3 Mn people die each year from COPD. Increasing pollution levels and changing lifestyles have contributed to the rising caseload of lung illnesses. The market also benefits from the superior therapeutic efficacy of inhalable drugs in treating conditions, affecting the respiratory tract directly. Technological advancements in drug delivery devices such as metered-dose inhalers (MDIs) and dry powder inhalers (DPIs) are expanding opportunities for novel therapies. However, high costs that are associated with development and production of inhalable drugs limit wider market growth. Additional constraints include stringent regulations around clinical trials and product approval for pulmonary drug delivery systems. Nevertheless, ongoing research and development (R&D) into advanced formulations and combination therapies could unlock new avenues over the forecast period.
Key features of the study:
- This report provides in-depth analysis of the global inhalable drugs market, and provides market size (US$ Bn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global inhalable drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include GSK plc, Mundipharma International., Boehringer Ingelheim International GmbH., Cipla Inc., AstraZeneca, Sanofi, Vectura Group Ltd, Viatris Inc, 3M Health Care, Allied Healthcare Products, Inc., CareFusion Corporation, GF Health Products, Inc., Merck & Co., Inc., Novartis AG, Omron Healthcare, Inc., Glenmark Pharmaceuticals and PARI Respiratory Equipment, Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global inhalable drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global inhalable drugs market
Detailed Segmentation:
- Global Inhalable Drugs Market, By Drug Class
- Inhaled Corticosteroids
- Leukotriene modifiers
- Long-acting beta agonists (LABAs)
- Long-acting muscarinic antagonists (LAMAs)
- Others
- Global Inhalable Drugs Market, By Product Type
- Aerosol
- Dry powder Formulation
- Spray
- Others
- Global Inhalable Drugs Market, By Application
- Respiratory Diseases
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Global Inhalable Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Inhalable Drugs Market, By Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
- Company Profiles
- GSK plc.
- Mundipharma International.
- Boehringer Ingelheim International GmbH.
- Cipla Inc.
- AstraZeneca
- Sanofi
- Vectura Group Ltd.
- Viatris Inc.
- 3M Health Care
- Allied Healthcare Products, Inc.
- CareFusion Corporation
- GF Health Products, Inc.
- Merck & Co., Inc.
- Novartis AG
- Omron Healthcare, Inc.
- Glenmark Pharmaceuticals
- PARI Respiratory Equipment, Inc.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Inhalable Drugs Market, By Drug Class
- Global Inhalable Drugs Market, By Product Type
- Global Inhalable Drugs Market, By Application
- Global Inhalable Drugs Market, By Distribution Channel
- Global Inhalable Drugs Market, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Growing prevalence of respiratory diseases
- Risk of misuse of inhalable medicines
- Emergence of new drug delivery technologies
- Key Highlights
- Regulatory Scenario
- Recent Trends
- PEST Analysis
- PORTER's Analysis
- Mergers, Acquisitions, and Collaborations
4. Global Inhalable Drugs Market- Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Inhalable Drugs Market, By Drug Class, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Inhaled Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Leukotriene modifiers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting beta antagonists (LABAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Long-acting muscarinic antagonists (LAMAs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
6. Global Inhalable Drugs Market, By Product Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Aerosol
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Dry powder Formulation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
7. Global Inhalable Drugs Market, By Application, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Respiratory Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Cystic Fibrosis
- Allergic Rhinitis
- Others
- Non-respiratory Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
8. Global Inhalable Drugs Market, By Distribution Channel, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032,(US$ Bn)
9. Global Inhalable Drugs Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Region, 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- U.S.
- Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032,(US$ Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Application, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032,(US$ Bn)
- North Africa
- Central Africa
- South Africa
10. Competitive Landscape
- Company Profile
- GSK plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Mundipharma International.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cipla Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Strategies
- Vectura Group Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Viatris Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 3M Health Care
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Allied Healthcare Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- CareFusion Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GF Health Products, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Omron Healthcare, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Glenmark Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PARI Respiratory Equipment, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Reference
- Research Methodology
- About us
